Project Description

CURE MEMBER DIRECTORY

Alexion-225px_w-V2

Alexion Pharmaceuticals

100 College Street
New Haven, CT 06510

Phone: 203-271-8296
Fax: 203-271-8192
Website: alexion.com

Contact
Corporate Communications

General Information
Alexion is a global biopharmaceutical company focused on developing and delivering life-transforming therapies for patients with devastating and rare disorders. Alexion developed and commercializes Soliris® (eculizumab), the first and only approved complement inhibitor to treat patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS), two life-threatening ultra-rare disorders. As the global leader in complement inhibition, Alexion is strengthening and broadening its portfolio of complement inhibitors, including evaluating potential indications for eculizumab in additional severe and ultra-rare disorders. Alexion’s metabolic franchise includes two highly innovative enzyme replacement therapies for patients with life-threatening and ultra-rare disorders, Strensiq® (asfotase alfa) to treat patients with hypophosphatasia (HPP) and Kanuma® (sebelipase alfa) to treat patients with lysosomal acid lipase deficiency (LAL-D). In addition, Alexion is advancing the most robust rare disease pipeline in the biotech industry with highly innovative product candidates in multiple therapeutic areas.

Research Activities
Complement inhibition, hematology, nephrology, transplant, neurology, metabolic disorders and inflammatory disorders.

Other Information
Ownership: Public
Stock Symbol: ALXN
CT Employees: 1,200
World Employees: 3,000

> Return to CURE Member Directory